Genomics – a blueprint for successful outcomes?

This month marks the 16th anniversary of the first full publication of the human genome. Far from being old news, the potential of genomics continues to grow. In what’s already a period of transformation for Life Sciences companies, how can they drive value from genomics, and what are the pitfalls to be avoided?
3 1

First harbingers of an incipient dynamic in the Swiss corporate tax landscape

Which Swiss cantons offer the greatest tax advantages to corporations? How do Swiss tax rates compare across the globe? Get the answers and deeper insight from KPMG’s latest Swiss Tax Report 2019.
1

Leitfaden für sicheres Cloud Banking

Am 26. März 2019 hat die Schweizerische Bankiervereinigung zusammen mit Mitgliedsinstituten, Prüfungsgesellschaften und Providern einen Leitfaden für Cloud Banking publiziert. Wozu dient der Leitfaden?
1

Refining relabeling of pharmaceuticals

Patient safety is at the heart of drug development and licensing processes. But the duty of care does not stop at launch. Manufacturers must satisfy strict regulatory demands throughout a product’s lifecycle, including re-labeling.
1

4 steps corporates should take to prepare for LIBOR transition

It’s clear the LIBOR transition will have a huge impact on financial institutions. But corporates aren’t immune to the changes. Have you assessed how the LIBOR shift will impact your business? Find out what steps your business can take to stay ahead of the curve.
1

Implication of the U.S. Cloud Act on Privacy Aspects

In March 2018 the U.S. Congress enacted the U.S. Cloud Act. From an EU-perspective there is significant concern that U.S. authorities might undermine the EU GDPR requirements by compelling U.S. providers to allow access to certain types of data stored outside the U.S.
1